Summary:
AqueSys develops a surgical device for the treatment of glaucoma.
AqueSys develops a surgical device for the treatment of glaucoma.
Investors 1
| Date | Name | Website |
| - | Rho Ventur... | rhoventure... |
Mentions in press and media 14
| Date | Title | Description |
| 22.01.2014 | AqueSys raises $43.6M and closes U.S. trial of XEN Gel glaucoma stent | California ophthalmic devices maker AqueSys touted a couple of milestones today, landing a successful $43.6 million Series D funding round and closing enrollment in U.S. clinical trial of its XEN Gel stent for treatment of glaucoma. The fun... |
| 19.11.2010 | Archemix Announces $315M Product Acquisition Deal with Baxter | Baxter International Inc. (NYSE: BAX) has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certa... |
| 29.06.2010 | AqueSys Gets $35M | Irvine-based AqueSys, a developer of medical devices for the treatment of glaucoma, said today that it has raised $35M in a Series C funding round. The round was led by Longitude Capital and Rho Ventures, and also included Accuitive Medical... |
| 29.06.2010 | AqueSys Secures $35M in Series C Financing | AqueSys, Inc., an Irvine, California-based medical device company that develops, manufactures and distributes proprietary implants for glaucoma, has secured $35m in Series C financing. The round was led by Longitude Capital and Rho Ventures... |
| 23.05.2008 | Lies, Damned Lies, and Statistics: The Definitive Rundown on New England Biotech | Share Share on Facebook Share on Twitter LinkedIn Email Reprints It’s official: 2007 rocked for New England biotech. Whether you look at IPOs, mergers, or venture activity, the region is consistently among the nation’s leaders. And on a per... |
| 07.02.2008 | IPO roundup: Is the window slamming on life sciences? | It’s sure starting to look that way. News that Archemix, a Cambridge, Mass., developer of aptamer-based drugs, yesterday withdrew its $72.5 million IPO follows closely on the heels of several other recent several other IPO collapses, includ... |
| 07.02.2008 | Life-science IPOs hit the skids | Last year was a tough one for IPOs, as Matt noted earlier, and so far this year looks even worse. Aptamer-drug maker Archemix today became the third life-science startup this month to withdraw or postpone an IPO, and the sixth so far this y... |
| 23.10.2007 | Life sciences briefing: Tuesday, Oct. 23, 2007 | Featured companies: Apex Radiology, Arcxis Biotechnologies, EKR Therapeutics, Franklin & Seidelmann, Michelson Diagnostics, SensiGen, Vascular Closure Systems UPDATED: Expanded items on Arcxis, Vascular Closure and Archemix. Arcxis pull... |
| 16.08.2007 | Double vision: Ophthotech, Eyetech and Lux BioSciences | When news that the brand-new startup Ophthotech had raised a $36 million first round broke on Monday, it was clear that the venture amounted to a kind of do-over for officials of the late, unlamented Eyetech Pharmaceuticals. Eyetech, you mi... |
| 13.08.2007 | Life sciences briefing: Monday, Aug. 13, 2007 | (UPDATED: See below.) Featured companies: FoldRx Pharmaceuticals, Ophthotech, Pevion Biotech, Restoration Robotics, Glide Pharma, Reliant Pharmaceuticals, Nanosphere, SurModics, BioFX Laboratories FoldRx Pharma to receive $22M against cysti... |
Show more